CompletedPhase 1NCT01702857

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)

Studying Dengue fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
U.S. Army Medical Research and Development Command
Principal Investigator
Clemente Diaz, MD, MD
University of Puerto Rico
Intervention
Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant(biological)
Enrollment
100 enrolled
Eligibility
20-39 years · All sexes
Timeline
2012 – 2017

Study locations (1)

Collaborators

GlaxoSmithKline · Walter Reed Army Institute of Research (WRAIR)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01702857 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials